Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Laurie Gaspar

Concepts (490)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Brain Neoplasms
100
2022
1163
6.610
 Why?
Lung Neoplasms
91
2023
2328
5.420
 Why?
Carcinoma, Non-Small-Cell Lung
54
2022
1045
4.290
 Why?
Radiosurgery
44
2022
318
4.140
 Why?
Cranial Irradiation
20
2022
68
2.810
 Why?
Small Cell Lung Carcinoma
11
2023
89
2.690
 Why?
Combined Modality Therapy
62
2022
1204
1.280
 Why?
Radiation Pneumonitis
5
2021
28
1.250
 Why?
Radiotherapy, Intensity-Modulated
9
2018
128
1.230
 Why?
Antineoplastic Combined Chemotherapy Protocols
30
2023
1559
1.190
 Why?
Practice Guidelines as Topic
13
2021
1478
1.160
 Why?
Carcinoma, Small Cell
8
2007
168
1.150
 Why?
Neoplasm Staging
39
2020
1290
1.120
 Why?
Radiotherapy Dosage
39
2023
249
1.070
 Why?
Chemoradiotherapy
8
2020
209
1.040
 Why?
Brachytherapy
12
2017
103
0.970
 Why?
Radiotherapy Planning, Computer-Assisted
11
2021
123
0.920
 Why?
Neoplasm Recurrence, Local
21
2017
958
0.910
 Why?
Glioblastoma
18
2016
322
0.890
 Why?
Radiation Oncology
12
2022
75
0.880
 Why?
Liver Neoplasms
8
2009
633
0.770
 Why?
Glioma
15
2015
353
0.760
 Why?
Adenocarcinoma
13
2022
888
0.750
 Why?
Aged
102
2020
21953
0.740
 Why?
Esophageal Neoplasms
9
2008
293
0.720
 Why?
Humans
221
2023
128417
0.710
 Why?
Survival Rate
31
2018
1869
0.710
 Why?
Prognosis
45
2022
3772
0.710
 Why?
Middle Aged
118
2020
30889
0.690
 Why?
Radiotherapy, Conformal
8
2017
70
0.680
 Why?
Clinical Trials as Topic
18
2018
993
0.670
 Why?
Radiotherapy
14
2017
185
0.660
 Why?
Radiotherapy, Adjuvant
16
2022
209
0.650
 Why?
Neurosurgeons
1
2019
18
0.630
 Why?
Dacarbazine
9
2016
97
0.630
 Why?
Evidence-Based Medicine
10
2021
711
0.610
 Why?
Four-Dimensional Computed Tomography
6
2021
28
0.600
 Why?
Oncologists
1
2018
35
0.560
 Why?
Patient Selection
10
2019
663
0.560
 Why?
Aged, 80 and over
45
2020
7033
0.550
 Why?
Clinical Decision-Making
3
2021
304
0.540
 Why?
Male
128
2022
62857
0.540
 Why?
Carcinoma, Squamous Cell
10
2017
620
0.540
 Why?
Cisplatin
18
2021
297
0.530
 Why?
Female
131
2020
68153
0.520
 Why?
Physician's Role
1
2018
206
0.510
 Why?
Antineoplastic Agents, Alkylating
8
2016
69
0.500
 Why?
Antineoplastic Agents
20
2017
2051
0.500
 Why?
Induction Chemotherapy
2
2013
70
0.470
 Why?
Adult
90
2020
35299
0.460
 Why?
Receptor Protein-Tyrosine Kinases
5
2017
221
0.440
 Why?
Survival Analysis
24
2020
1263
0.440
 Why?
Treatment Outcome
36
2021
10151
0.430
 Why?
Physician-Patient Relations
1
2018
535
0.410
 Why?
Etoposide
12
2021
149
0.400
 Why?
Pro-Opiomelanocortin
7
1989
17
0.380
 Why?
Pneumonectomy
2
2015
150
0.370
 Why?
Retrospective Studies
40
2022
14454
0.370
 Why?
Astrocytoma
9
2014
121
0.360
 Why?
Societies, Medical
7
2021
745
0.330
 Why?
Protein Kinase Inhibitors
4
2021
872
0.330
 Why?
Pulmonary Ventilation
4
2021
76
0.320
 Why?
Whole-Body Irradiation
1
2009
75
0.320
 Why?
Melanoma
5
2018
752
0.320
 Why?
Guidelines as Topic
2
2020
260
0.320
 Why?
Chemotherapy, Adjuvant
12
2017
376
0.320
 Why?
Guideline Adherence
4
2018
521
0.320
 Why?
Medical Oncology
7
2021
271
0.320
 Why?
Karnofsky Performance Status
11
2020
38
0.320
 Why?
ErbB Receptors
8
2022
601
0.310
 Why?
Lung
9
2021
3743
0.310
 Why?
Quinazolines
6
2014
243
0.300
 Why?
Breast Neoplasms
9
2020
2132
0.300
 Why?
Dose-Response Relationship, Radiation
11
2019
132
0.300
 Why?
Iodine Radioisotopes
6
2006
142
0.290
 Why?
Re-Irradiation
2
2018
8
0.290
 Why?
Radiopharmaceuticals
5
2014
166
0.290
 Why?
Controlled Clinical Trials as Topic
1
2007
27
0.290
 Why?
Neoplasm Metastasis
8
2019
608
0.290
 Why?
Disease Progression
13
2018
2602
0.280
 Why?
Follow-Up Studies
22
2018
4892
0.280
 Why?
Anticonvulsants
2
2019
197
0.270
 Why?
Tumor Burden
9
2017
283
0.270
 Why?
Biomarkers, Tumor
6
2021
1181
0.260
 Why?
Tomography, X-Ray Computed
10
2018
2523
0.250
 Why?
Paclitaxel
5
2011
214
0.250
 Why?
Prospective Studies
22
2018
7036
0.250
 Why?
Proto-Oncogene Proteins B-raf
2
2017
214
0.240
 Why?
Spinal Cord
4
2018
353
0.240
 Why?
Carcinoma, Hepatocellular
2
2005
270
0.230
 Why?
Steroids
2
2019
147
0.230
 Why?
Taxoids
5
2015
95
0.220
 Why?
Central Nervous System
2
2017
254
0.220
 Why?
Carcinoma
1
2006
214
0.220
 Why?
Lymphatic Metastasis
3
2017
318
0.220
 Why?
Magnetic Resonance Imaging
9
2019
3376
0.220
 Why?
Carcinoma, Renal Cell
3
2018
179
0.210
 Why?
Gastrointestinal Neoplasms
3
2019
72
0.210
 Why?
Randomized Controlled Trials as Topic
7
2021
1356
0.200
 Why?
Radiography
8
2014
859
0.190
 Why?
Necrosis
3
2019
229
0.190
 Why?
Positron Emission Tomography Computed Tomography
2
2020
84
0.190
 Why?
Medical Illustration
2
2012
9
0.190
 Why?
Organs at Risk
2
2012
31
0.190
 Why?
Ribs
2
2012
33
0.190
 Why?
Brachial Plexus
2
2012
28
0.190
 Why?
Neoplasms
6
2020
2464
0.180
 Why?
Professional Staff Committees
4
2001
13
0.180
 Why?
Oligodendroglioma
4
2014
15
0.180
 Why?
Esophagectomy
1
2002
124
0.180
 Why?
Testicular Neoplasms
1
2022
102
0.170
 Why?
Mutation
4
2021
3689
0.170
 Why?
Proportional Hazards Models
8
2020
1196
0.170
 Why?
Research Design
7
2018
1036
0.170
 Why?
Peptide Fragments
4
1989
684
0.170
 Why?
Thymus Neoplasms
2
2017
22
0.160
 Why?
Thymoma
2
2017
31
0.160
 Why?
Time Factors
10
2019
6482
0.160
 Why?
Consolidation Chemotherapy
1
2019
9
0.160
 Why?
Esophagus
2
2012
248
0.160
 Why?
Metalloporphyrins
3
2011
101
0.160
 Why?
Maximum Tolerated Dose
6
2010
192
0.160
 Why?
Radiation Injuries
5
2015
135
0.160
 Why?
Congresses as Topic
2
2019
212
0.160
 Why?
Meningeal Neoplasms
3
2017
93
0.160
 Why?
Watchful Waiting
1
2019
65
0.160
 Why?
Expert Testimony
1
2019
36
0.150
 Why?
Aquaporin 4
1
2019
96
0.150
 Why?
Gray Matter
1
2019
82
0.150
 Why?
CTLA-4 Antigen
1
2018
89
0.150
 Why?
Spinal Neoplasms
1
2018
29
0.150
 Why?
Cognition
4
2013
1107
0.140
 Why?
Intracranial Arteriovenous Malformations
2
1995
50
0.140
 Why?
Carboplatin
4
2011
140
0.140
 Why?
Intersectoral Collaboration
1
2018
61
0.140
 Why?
Kidney Neoplasms
3
2018
349
0.140
 Why?
Receptor, ErbB-2
5
2020
325
0.140
 Why?
Endpoint Determination
1
2018
75
0.140
 Why?
Quality of Life
5
2013
2680
0.140
 Why?
Treatment Failure
5
2014
339
0.140
 Why?
Professional Competence
1
2018
95
0.140
 Why?
Genes, ras
1
2017
98
0.140
 Why?
Antineoplastic Agents, Immunological
1
2019
175
0.140
 Why?
Triazines
2
2009
38
0.130
 Why?
Decision Trees
1
1997
89
0.130
 Why?
Mortality
1
2019
307
0.130
 Why?
Pituitary Neoplasms
5
1994
184
0.130
 Why?
Proto-Oncogene Proteins c-kit
1
2017
68
0.130
 Why?
Interdisciplinary Communication
1
2018
187
0.130
 Why?
Brain
5
2019
2620
0.130
 Why?
Fluorouracil
6
2004
197
0.130
 Why?
Salvage Therapy
4
2017
138
0.130
 Why?
Hemangioma, Cavernous
2
1993
13
0.130
 Why?
Cohort Studies
7
2019
5388
0.130
 Why?
Programmed Cell Death 1 Receptor
1
2018
228
0.130
 Why?
Antibodies
1
2018
391
0.130
 Why?
Age Factors
8
2017
3103
0.130
 Why?
Pulmonary Atelectasis
1
2015
13
0.130
 Why?
Accreditation
2
2013
79
0.130
 Why?
Patient Preference
1
2018
185
0.120
 Why?
Adrenal Cortex Hormones
1
2019
518
0.120
 Why?
Radiation-Sensitizing Agents
5
2009
40
0.120
 Why?
United States
13
2022
13830
0.120
 Why?
Postoperative Care
1
2017
241
0.120
 Why?
Medically Underserved Area
1
2016
83
0.120
 Why?
Radiographic Image Interpretation, Computer-Assisted
1
2015
96
0.120
 Why?
Antineoplastic Agents, Phytogenic
2
2006
185
0.120
 Why?
Central Nervous System Neoplasms
1
2017
148
0.120
 Why?
Risk Assessment
3
2021
3232
0.110
 Why?
Carmustine
7
2010
50
0.110
 Why?
Triple Negative Breast Neoplasms
1
2017
191
0.110
 Why?
Perfusion Imaging
1
2014
56
0.110
 Why?
Analysis of Variance
5
2014
1269
0.110
 Why?
Fibrosarcoma
1
1993
20
0.110
 Why?
Camptothecin
2
2011
106
0.110
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2014
19
0.110
 Why?
Adolescent
22
2017
20179
0.110
 Why?
Cerebellar Neoplasms
2
1996
156
0.110
 Why?
Receptors, Progesterone
4
2020
341
0.110
 Why?
Contraindications
2
2008
88
0.110
 Why?
Nelson Syndrome
4
1987
4
0.110
 Why?
Pyrazoles
2
2014
404
0.110
 Why?
Medulloblastoma
2
1996
198
0.110
 Why?
Kaplan-Meier Estimate
5
2019
853
0.100
 Why?
Disease-Free Survival
6
2014
647
0.100
 Why?
Pyridines
2
2014
475
0.100
 Why?
Respiratory Function Tests
1
2015
580
0.100
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1351
0.100
 Why?
beta-Endorphin
3
1989
8
0.100
 Why?
Pancreatic Neoplasms
1
2000
875
0.100
 Why?
Radiotherapy, High-Energy
4
2000
13
0.100
 Why?
Particle Accelerators
1
1991
10
0.090
 Why?
Adrenocorticotropic Hormone
3
1989
132
0.090
 Why?
Bone Neoplasms
3
2007
229
0.090
 Why?
Radiation Protection
2
2009
37
0.090
 Why?
Quality Assurance, Health Care
3
2009
316
0.090
 Why?
Forced Expiratory Volume
2
2015
509
0.090
 Why?
Young Adult
8
2017
12312
0.090
 Why?
Hyperthermia, Induced
1
1992
108
0.090
 Why?
Databases, Factual
5
2017
1269
0.090
 Why?
Technology, Radiologic
1
2010
6
0.090
 Why?
Radiotherapy, Computer-Assisted
1
2010
12
0.090
 Why?
Bevacizumab
3
2015
129
0.080
 Why?
MEDLINE
1
2009
20
0.080
 Why?
Spine
1
1991
157
0.080
 Why?
Clinical Trials, Phase II as Topic
2
2002
71
0.080
 Why?
Severity of Illness Index
2
2008
2721
0.080
 Why?
Adenoma
4
1994
213
0.080
 Why?
Multivariate Analysis
6
2020
1484
0.080
 Why?
Neurosurgery
1
2009
38
0.080
 Why?
Risk Factors
7
2021
9704
0.080
 Why?
Adrenal Medulla
1
1989
7
0.080
 Why?
Palliative Care
5
2018
713
0.080
 Why?
Neurotensin
1
1989
12
0.080
 Why?
Drug Therapy
1
2009
77
0.080
 Why?
Education, Medical, Graduate
1
2013
435
0.080
 Why?
Catheter Ablation
1
2012
332
0.080
 Why?
Fractures, Spontaneous
1
1988
12
0.080
 Why?
Meta-Analysis as Topic
1
2009
169
0.080
 Why?
Piperidines
1
2010
190
0.080
 Why?
Ependymoma
2
2009
176
0.080
 Why?
Imaging, Three-Dimensional
2
2010
533
0.080
 Why?
Esophageal Fistula
2
2000
18
0.080
 Why?
Liver
2
2008
1826
0.080
 Why?
Equipment Failure Analysis
1
2009
131
0.080
 Why?
Radionuclide Imaging
1
2008
123
0.070
 Why?
Pheochromocytoma
1
1989
57
0.070
 Why?
Respiratory Mechanics
1
2008
63
0.070
 Why?
Humeral Fractures
1
1988
48
0.070
 Why?
Positron-Emission Tomography
2
2008
283
0.070
 Why?
Femoral Fractures
1
1988
74
0.070
 Why?
Adrenal Gland Neoplasms
1
1989
83
0.070
 Why?
Lymph Node Excision
1
2009
165
0.070
 Why?
Surveys and Questionnaires
2
2018
5362
0.070
 Why?
Craniopharyngioma
1
2009
82
0.070
 Why?
Chromatography, Gel
4
1989
127
0.070
 Why?
Kidney
2
2005
1302
0.070
 Why?
Pulmonary Disease, Chronic Obstructive
1
2015
945
0.070
 Why?
Statistics, Nonparametric
2
2018
418
0.070
 Why?
Radioimmunoassay
4
1989
169
0.070
 Why?
Uterine Cervical Neoplasms
1
1989
232
0.070
 Why?
Biomedical Research
2
2009
635
0.060
 Why?
Seizures
1
2009
399
0.060
 Why?
Clinical Competence
1
2013
1013
0.060
 Why?
Vascular Diseases
1
2009
232
0.060
 Why?
Whole Body Imaging
1
2006
20
0.060
 Why?
Genetic Markers
2
2017
338
0.060
 Why?
Neoplasm Grading
2
2020
283
0.060
 Why?
Hepatitis B, Chronic
1
2005
18
0.060
 Why?
Linear Models
3
2017
813
0.060
 Why?
Drug Administration Schedule
3
2014
751
0.060
 Why?
Vascular Endothelial Growth Factor A
1
2008
500
0.060
 Why?
Strontium Radioisotopes
2
2006
3
0.060
 Why?
Databases as Topic
1
2005
59
0.060
 Why?
Diagnostic Imaging
3
2009
330
0.060
 Why?
Hemoglobins
1
2007
336
0.060
 Why?
Immunotherapy
2
2022
587
0.060
 Why?
Peptides
3
1985
908
0.060
 Why?
Antiemetics
1
2005
39
0.060
 Why?
Anticoagulants
1
2009
613
0.060
 Why?
Gene Rearrangement
2
2018
146
0.060
 Why?
Delivery of Health Care
1
2012
895
0.060
 Why?
Pituitary Hormones
1
1984
16
0.060
 Why?
Organ Size
1
2005
440
0.060
 Why?
Physicians
1
2013
858
0.060
 Why?
Body Fluids
1
1985
62
0.060
 Why?
Retreatment
3
2012
69
0.060
 Why?
Cognition Disorders
2
2010
497
0.060
 Why?
Practice Patterns, Physicians'
1
2013
1258
0.060
 Why?
Dexamethasone
3
2012
338
0.060
 Why?
Age Distribution
1
2005
371
0.060
 Why?
Feasibility Studies
3
2011
860
0.060
 Why?
Sex Distribution
1
2005
358
0.060
 Why?
Consensus
2
2021
613
0.060
 Why?
Regression Analysis
2
2017
978
0.050
 Why?
Erlotinib Hydrochloride
2
2014
69
0.050
 Why?
Hepatitis C, Chronic
1
2005
152
0.050
 Why?
Internship and Residency
1
2013
1048
0.050
 Why?
Liver Cirrhosis
1
2005
275
0.050
 Why?
Preoperative Care
1
2005
338
0.050
 Why?
Propionates
1
2003
33
0.050
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2006
253
0.050
 Why?
Chromatography, Affinity
3
1989
83
0.050
 Why?
Aniline Compounds
1
2003
98
0.050
 Why?
Societies
1
2022
36
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2004
90
0.050
 Why?
Pterygium
1
2000
4
0.040
 Why?
Algorithms
2
2017
1618
0.040
 Why?
Organizational Objectives
4
2001
72
0.040
 Why?
Esophagoscopy
1
2002
195
0.040
 Why?
Reproducibility of Results
2
2015
3020
0.040
 Why?
Ontario
2
2017
89
0.040
 Why?
B7-H1 Antigen
1
2022
189
0.040
 Why?
Neurologic Examination
1
2000
115
0.040
 Why?
Vincristine
2
2010
109
0.040
 Why?
BRCA1 Protein
1
2020
65
0.040
 Why?
Carcinoma, Bronchogenic
1
1999
19
0.040
 Why?
Spinal Cord Neoplasms
1
1999
39
0.040
 Why?
Neuropsychological Tests
3
2013
1002
0.040
 Why?
Carcinoma, Large Cell
1
1999
15
0.040
 Why?
Receptors, Estrogen
2
2013
424
0.040
 Why?
Medical Records
2
2010
170
0.040
 Why?
Reoperation
2
2012
557
0.040
 Why?
Liver Transplantation
1
2005
798
0.040
 Why?
Urinary Bladder Neoplasms
1
2001
226
0.040
 Why?
Estrogens
1
2020
342
0.040
 Why?
Child, Preschool
7
2009
10384
0.040
 Why?
Thoracic Vertebrae
1
2018
73
0.040
 Why?
Iridium Radioisotopes
1
1997
3
0.030
 Why?
Colorado
3
2014
4375
0.030
 Why?
Epidemiologic Methods
1
2017
73
0.030
 Why?
Aziridines
2
1994
5
0.030
 Why?
Clinical Trials, Phase I as Topic
1
1997
50
0.030
 Why?
Biopsy, Needle
1
2017
188
0.030
 Why?
Molecular Weight
2
1989
331
0.030
 Why?
Precision Medicine
1
2020
384
0.030
 Why?
Memory Disorders
2
2010
157
0.030
 Why?
Skin Neoplasms
2
2017
832
0.030
 Why?
Esophagitis
2
2009
67
0.030
 Why?
Benzoquinones
2
1994
47
0.030
 Why?
Propensity Score
1
2018
264
0.030
 Why?
Respiration
1
2017
190
0.030
 Why?
Neutropenia
2
2009
134
0.030
 Why?
Supratentorial Neoplasms
1
1996
19
0.030
 Why?
Odds Ratio
1
1999
1023
0.030
 Why?
Heart
1
2020
635
0.030
 Why?
Meningioma
1
1997
81
0.030
 Why?
Estrogen Receptor alpha
1
2017
132
0.030
 Why?
Sex Factors
2
2014
1945
0.030
 Why?
Pilot Projects
3
2015
1563
0.030
 Why?
Cerebral Angiography
1
1995
109
0.030
 Why?
Forecasting
3
2001
358
0.030
 Why?
Marital Status
1
2014
44
0.030
 Why?
Myocardium
1
2020
965
0.030
 Why?
Technetium Tc 99m Pentetate
1
2014
7
0.030
 Why?
Nuclear Medicine
1
2014
7
0.030
 Why?
Ventilation-Perfusion Ratio
1
2014
10
0.030
 Why?
Patient Safety
1
2017
287
0.030
 Why?
Vital Capacity
1
2015
288
0.030
 Why?
Nervous System Diseases
1
1997
252
0.030
 Why?
Child
9
2009
20655
0.030
 Why?
Texas
1
2014
227
0.030
 Why?
Molecular Targeted Therapy
1
2017
385
0.030
 Why?
Radioisotope Teletherapy
1
1993
2
0.030
 Why?
Cobalt Radioisotopes
1
1993
7
0.030
 Why?
SEER Program
1
2014
206
0.030
 Why?
Developing Countries
1
2016
285
0.030
 Why?
Spatial Analysis
1
2013
21
0.030
 Why?
Radiodermatitis
1
1993
8
0.030
 Why?
Vimentin
1
1993
50
0.030
 Why?
Radiometry
1
2013
48
0.030
 Why?
Monte Carlo Method
1
2013
137
0.030
 Why?
Observer Variation
1
2014
312
0.030
 Why?
Scalp
1
1993
34
0.030
 Why?
Prostatic Neoplasms
1
2001
1011
0.030
 Why?
Cerebral Cortex
1
1996
423
0.030
 Why?
Time
1
2013
75
0.030
 Why?
Protein-Tyrosine Kinases
1
2016
430
0.030
 Why?
Mitosis
1
1993
178
0.030
 Why?
Ascorbic Acid
1
1993
120
0.030
 Why?
Medical Errors
1
2013
104
0.020
 Why?
Radiation Dosage
1
2013
152
0.020
 Why?
Remission Induction
2
2008
268
0.020
 Why?
Radiology
1
2014
161
0.020
 Why?
Disease Management
1
2016
587
0.020
 Why?
International Agencies
1
2011
29
0.020
 Why?
Diagnosis, Differential
1
2015
1416
0.020
 Why?
Electrons
1
1991
78
0.020
 Why?
Breast Neoplasms, Male
1
2011
29
0.020
 Why?
Bronchography
1
2010
10
0.020
 Why?
Sensitivity and Specificity
1
2015
1815
0.020
 Why?
Longitudinal Studies
1
2018
2710
0.020
 Why?
Infusions, Intravenous
2
2004
385
0.020
 Why?
Fibrosis
1
2013
512
0.020
 Why?
Cell Nucleus
1
1993
578
0.020
 Why?
Procarbazine
1
1990
8
0.020
 Why?
Lomustine
1
1990
14
0.020
 Why?
Physics
1
2010
17
0.020
 Why?
Chromatin
1
1993
477
0.020
 Why?
Neoplasm, Residual
1
2010
119
0.020
 Why?
Selection Bias
1
2009
37
0.020
 Why?
Clinical Trials Data Monitoring Committees
1
2009
6
0.020
 Why?
Hypophysectomy
1
1989
15
0.020
 Why?
Smoking
1
2017
1460
0.020
 Why?
Quality Control
1
2010
156
0.020
 Why?
Incidence
1
2016
2616
0.020
 Why?
Prevalence
1
2016
2547
0.020
 Why?
Immunohistochemistry
1
1993
1664
0.020
 Why?
Platinum
1
2009
44
0.020
 Why?
Certification
1
2010
94
0.020
 Why?
Adrenal Cortex
1
1989
27
0.020
 Why?
Bronchi
1
2010
240
0.020
 Why?
Neoplasms, Unknown Primary
1
1988
13
0.020
 Why?
Hepatic Veno-Occlusive Disease
1
2008
14
0.020
 Why?
Prostheses and Implants
1
2010
136
0.020
 Why?
Liver Regeneration
1
2008
40
0.020
 Why?
beta-Lipotropin
2
1985
2
0.020
 Why?
Endorphins
2
1985
8
0.020
 Why?
Anti-Inflammatory Agents
1
2012
468
0.020
 Why?
Polymorphism, Single Nucleotide
1
2016
2062
0.020
 Why?
Epinephrine
1
1989
136
0.020
 Why?
Administration, Oral
1
2010
754
0.020
 Why?
Motion
1
2008
98
0.020
 Why?
International Cooperation
1
2008
171
0.020
 Why?
Infant
4
1999
8914
0.020
 Why?
Mental Status Schedule
1
2007
34
0.020
 Why?
Fracture Fixation, Intramedullary
1
1988
63
0.020
 Why?
Reference Values
1
1989
776
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2264
0.020
 Why?
Rectal Neoplasms
1
2008
136
0.020
 Why?
Bleomycin
1
2009
240
0.020
 Why?
Creatinine
1
1989
475
0.020
 Why?
Chromatography, High Pressure Liquid
1
1989
475
0.020
 Why?
Predictive Value of Tests
2
2008
1935
0.020
 Why?
California
1
2008
398
0.020
 Why?
Southwestern United States
1
2006
91
0.020
 Why?
DNA Repair
1
2008
205
0.020
 Why?
Chromium Compounds
1
2006
2
0.020
 Why?
Sodium Iodide
1
2006
3
0.020
 Why?
Neovascularization, Pathologic
1
2008
290
0.020
 Why?
Methadone
1
1987
90
0.020
 Why?
Polycythemia Vera
1
2006
12
0.020
 Why?
Pleural Effusion, Malignant
1
2006
10
0.020
 Why?
Glucocorticoids
1
2010
571
0.020
 Why?
Hydrocephalus
1
1987
108
0.020
 Why?
Hyperthyroidism
1
2006
28
0.020
 Why?
Patient Isolation
1
2006
16
0.020
 Why?
Yttrium Radioisotopes
1
2006
52
0.020
 Why?
Ascites
1
2006
44
0.020
 Why?
DNA Damage
1
2008
364
0.020
 Why?
Lymphoma, Non-Hodgkin
1
2006
76
0.020
 Why?
Organophosphorus Compounds
1
2006
78
0.010
 Why?
Chromatography
1
1985
25
0.010
 Why?
Concanavalin A
1
1985
75
0.010
 Why?
Phosphates
1
2006
168
0.010
 Why?
Patient Education as Topic
1
2010
737
0.010
 Why?
Organometallic Compounds
1
2006
105
0.010
 Why?
ACTH Syndrome, Ectopic
1
1984
2
0.010
 Why?
Occipital Lobe
1
2004
24
0.010
 Why?
Biotransformation
1
1984
47
0.010
 Why?
Carbohydrate Metabolism
1
1984
60
0.010
 Why?
Brain Edema
1
2004
60
0.010
 Why?
Genomics
1
2009
715
0.010
 Why?
Recurrence
2
2000
996
0.010
 Why?
Arginine Vasopressin
1
1984
41
0.010
 Why?
Thrombocytopenia
1
2006
181
0.010
 Why?
Vomiting
1
2004
126
0.010
 Why?
Corticotropin-Releasing Hormone
1
1984
60
0.010
 Why?
Oils
1
1983
20
0.010
 Why?
Bipolar Disorder
1
1985
235
0.010
 Why?
Motor Skills
1
2004
91
0.010
 Why?
Thyroid Neoplasms
1
2006
309
0.010
 Why?
Immunologic Factors
1
2003
225
0.010
 Why?
Antimetabolites, Antineoplastic
1
2001
90
0.010
 Why?
Pain
1
2006
757
0.010
 Why?
Psychometrics
1
2004
681
0.010
 Why?
Opioid-Related Disorders
1
1987
480
0.010
 Why?
Postoperative Period
1
2000
324
0.010
 Why?
Thorax
1
1999
41
0.010
 Why?
Apoptosis
1
2008
2435
0.010
 Why?
Michigan
1
1999
103
0.010
 Why?
Antibodies, Monoclonal
1
2006
1355
0.010
 Why?
Cysts
1
1999
108
0.010
 Why?
Bias
1
1999
195
0.010
 Why?
Meninges
1
1997
43
0.010
 Why?
Mercaptopurine
1
1996
15
0.010
 Why?
Mitomycin
1
1996
31
0.010
 Why?
Cross-Sectional Studies
1
2007
5039
0.010
 Why?
Biopsy
1
1999
1081
0.010
 Why?
Autoantibodies
1
1983
1463
0.010
 Why?
Decision Making
1
2001
847
0.010
 Why?
Cause of Death
1
1996
393
0.010
 Why?
Solutions
1
1993
147
0.010
 Why?
Neoplasms, Radiation-Induced
1
1993
71
0.010
 Why?
Cerebral Hemorrhage
1
1993
106
0.010
 Why?
Computer Simulation
1
1995
939
0.010
 Why?
Patient Compliance
1
1994
560
0.010
 Why?
Evaluation Studies as Topic
1
1989
171
0.000
 Why?
Double-Blind Method
1
1993
1848
0.000
 Why?
Melanocyte-Stimulating Hormones
1
1985
2
0.000
 Why?
Lithium
1
1985
37
0.000
 Why?
Postoperative Complications
1
1996
2485
0.000
 Why?
Brassica
1
1983
4
0.000
 Why?
Spain
1
1983
35
0.000
 Why?
Drug Synergism
1
1984
359
0.000
 Why?
Antigen-Antibody Complex
1
1983
84
0.000
 Why?
Syndrome
1
1983
335
0.000
 Why?
In Vitro Techniques
1
1984
1039
0.000
 Why?
Sheep
1
1984
828
0.000
 Why?
Animals
1
1984
34479
0.000
 Why?
Gaspar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (490) concept(s)
_
Co-Authors Expand Description
See all (35) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)